Swiss drugmaker Roche has announced that its blood glucose meter system, Accu-Chek Aviva expert system, has received an approval of the US food and drug administration (FDA) will now be available by prescription.
The system will be available by prescription for people suffering from diabetes who are trained in injection therapy and are under the supervision of healthcare professionals.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Roche Diabetes Care North America head Marc Gibeley said: "The Accu-Chek Aviva Expert system is the first and only system of its kind that provides meal and correction insulin bolus recommendations, which can help patients on insulin therapy have the confidence they need to better manage their diabetes."
The glucose meter comes with a built-in insulin calculator and provides easy-to-use and reliable dose recommendations to diabetic patients who need to take multiple insulin injections every day.
The device’s integrated bolus calculator helps in eliminating the need for manual dosing calculations and estimations.
The company claimed that a survey of Accu-Chek Aviva Expert found that about 79% reported an increase in confidence regarding insulin dose calculation and 52% reported reduced fear of hypoglycemia.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataEmory University Department of Medicine clinical associate professor and a diabetes specialist with Atlanta Diabetes Associates Dr Bruce W Bode said: "The availability of the Accu-Chek Aviva Expert system marks an important, game-changing milestone in diabetes self-management by making the process of calculating insulin dosage easier and less susceptible to error.
"One of the biggest barriers to optimal self-management is the ability to calculate bolus doses. My hope is that the device will become the standard of care for patients on multiple daily insulin injection therapy due to the simplicity of the built-in bolus calculator."
Nearly 29.1 million people are affected by diabetes in the US. The technology will help in regular and accurate monitoring of blood glucose levels through self-testing which is essential to tackle the disease.
Image: The Accu-Chek Aviva expert system. Photo: courtesy of Roche.
